Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University , 24 Tong Jia Xiang, Nanjing 210009, People's Republic of China.
Anal Chem. 2017 Nov 21;89(22):12319-12326. doi: 10.1021/acs.analchem.7b03332. Epub 2017 Oct 30.
Leucine aminopeptidase (LAP) is a kind of proteolytic enzymes and associated closely with pathogenesis of cancer and liver injury. Accurate detection of LAP activity with high sensitivity and selectivity is imperative to detect its distribution and dynamic changes for understanding LAP's function and early diagnosing the disease states. However, fluorescent detection of LAP in living systems is challenging. To date, rarely fluorescent probes have been reported for imaging LAP in vivo. In this study, a novel probe (TMN-Leu) was developed by conjugating a near-infrared dicyanoisophorone derivative fluorophore with LAP activatable l-leucine amide moiety for the first time. TMN-Leu featured large Stokes shift (198 nm), favorable water solubility, ultrasensitive sensitivity (detection limit of ∼0.38 ng/mL), good specificity, excellent cell membrane permeability, low toxicity, and a prominent near-infrared emission (658 nm) in response to LAP. TMN-Leu has been successfully applied to track LAP of cancer cells and normal cells, monitor LAP changes in different disease models, and rapidly evaluate LAP inhibitor in cell-based assay. Notably, this probe firstly revealed that HCT116 cells with higher LAP activity were more invasive than LAP siRNA transfected HCT116 cells, suggesting that LAP might serve as an indicator reflecting the intrinsic invasion ability of cancer cells. Finally, TMN-Leu was also employed for in vivo real-time imaging LAP in living tumor-bearing nude mice with low background interference. All together, our probe possesses potential value as a promising tool for diagnostic application, cell-based screening inhibitors and in vivo real-time tracking enzymatic activity in preclinical applications.
亮氨酸氨肽酶(LAP)是一种蛋白水解酶,与癌症和肝损伤的发病机制密切相关。准确、灵敏、选择性地检测 LAP 活性对于检测其分布和动态变化、了解 LAP 的功能以及早期诊断疾病状态至关重要。然而,在活体内荧光检测 LAP 具有挑战性。迄今为止,很少有荧光探针被报道用于体内成像 LAP。在本研究中,我们首次通过将近红外二氰异戊烯衍生物荧光团与 LAP 激活的 l-亮氨酸酰胺部分缀合,开发了一种新型探针(TMN-Leu)。TMN-Leu 具有大的斯托克斯位移(198nm)、良好的水溶性、超灵敏的灵敏度(检测限约为 0.38ng/mL)、良好的特异性、优异的细胞膜通透性、低毒性以及对 LAP 的近红外发射(658nm)。TMN-Leu 已成功应用于跟踪癌细胞和正常细胞的 LAP、监测不同疾病模型中的 LAP 变化以及在基于细胞的测定中快速评估 LAP 抑制剂。值得注意的是,该探针首次揭示了 LAP 活性较高的 HCT116 细胞比 LAP siRNA 转染的 HCT116 细胞更具侵袭性,表明 LAP 可能作为反映癌细胞固有侵袭能力的指标。最后,TMN-Leu 还用于在活体荷瘤裸鼠中进行体内实时成像 LAP,具有低背景干扰。总之,我们的探针具有作为一种有前途的诊断应用工具的潜在价值,可用于细胞筛选抑制剂和临床前应用中体内实时跟踪酶活性。